GE Healthcare is set to invest $1bn from its total R&D budget over the next five years to expand its advanced cancer diagnostic, molecular imaging capabilities and its technologies to manufacture biopharmaceuticals and for cancer research.
The investment will focus on developing new oncology solutions and build on advanced technologies and research already in progress, including new biomarkers, molecular pathology, cancer research, hyperpolarizer, connected oncology workflow.
GE Healthcare vice president and CTO Mike Harsh said the only way they can help clinicians beat cancer is to give them the tools to find it earlier, stage it better, and quantitatively measure response to therapy.
"The integration of GE Healthcare’s expertise in imaging, analytics, diagnostics, cellular analysis, and healthcare IT is helping create technologies and solutions that can be used in a rural developing country or in a modern urban hospital," Harsh said.